Nobody dares stopping clinical research, not even COVID-19
Overview
Paper Summary
This study describes how a single company adapted its clinical trial operations during the first nine months of the COVID-19 pandemic, implementing measures like remote monitoring and telehealth visits. The limited scope to one company and relatively short timeframe are major limitations, restricting the generalizability of the findings.
Explain Like I'm Five
This paper describes how one company managed its ongoing clinical trials during the initial phase of the COVID-19 pandemic. They made changes like remote monitoring and virtual visits to keep trials going.
Possible Conflicts of Interest
Several authors are employed by MEDSIR, the company whose practices are the subject of the study. Additionally, several authors disclose financial ties to pharmaceutical companies.
Identified Limitations
Rating Explanation
This is a descriptive study with limited generalizability, providing a snapshot of one company's experience. While it offers valuable insights into adaptations made during a challenging time, its scope and methodology prevent a higher rating. The disclosed conflicts of interest also contribute to the lower rating.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →